← Back to Search

Antiplatelet Agent

Clopidogrel for Thrombocytopenia

Phase 4
Waitlist Available
Led By Joshua P Lewis, PhD
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 days of exposure to either clopidogrel or ticagrelor
Awards & highlights

Study Summary

This trial is looking at how well two different antiplatelet drugs work in people with different genetic variations.

Eligible Conditions
  • Thrombocytopenia
  • Blood Clot
  • Heart Attack

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 days of exposure to either clopidogrel or ticagrelor
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 days of exposure to either clopidogrel or ticagrelor for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
CES1 genotype-dependent effect of clopidogrel or ticagrelor on inhibition of platelet aggregation
Impact of alternative drug choice on CES1 genotype-dependent maximal platelet aggregation

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Carriers of the CES1 G143E MutationExperimental Treatment2 Interventions
Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
Group II: Carriers of CES1 Functional MutationExperimental Treatment2 Interventions
Research subjects who carry a CES1 mutation of potential functional impact (to be determined...studies ongoing) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
Group III: Wild-Type GenotypeActive Control2 Interventions
Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clopidogrel
2010
Completed Phase 4
~9160
Ticagrelor
2014
Completed Phase 4
~2720

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
688 Previous Clinical Trials
374,567 Total Patients Enrolled
Joshua P Lewis, PhDPrincipal InvestigatorUniversity of Maryland
2 Previous Clinical Trials
206 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What medical condition is Clopidogrel usually prescribed for?

"Clopidogrel is often prescribed to treat myocardial infarction, though it may also be effective in managing other cardiac conditions such as stent placement, cerebrovascular accident, and coronary artery disease."

Answered by AI

What is the enrolment capacity for this research project?

"Affirmative, according to clinicaltrials.gov this medical study is actively seeking participants. Originally posted on August 22nd 2017, the trial requires 90 individuals from 1 site and was last revised on January 24th 2022."

Answered by AI

Has Clopidogrel been previously explored in any scientific research?

"At this juncture, 78 experiments are underway examining the effects of Clopidogrel. Of these investigations, 20 have progressed to Phase 3 trials. Primarily situated in Beijing, there are 873 research centres dedicating resources towards exploring this medication's efficacy."

Answered by AI

For whom is the opportunity to participate in this experiment available?

"This clinical trial is in search of 90 individuals who are 18 to 75 years old, with thrombus and either Amish descent or a familial connection to the PAPI-1 Study."

Answered by AI

Does this research include adults aged 18 and up?

"This medical trial is accepting adult and elderly participants between the ages of 18 and 75."

Answered by AI

Are there any open opportunities to participate in this clinical experiment?

"As indicated on clinicaltrials.gov, this medical research is actively enrolling participants with the initial post date of August 22nd 2017 and a recent update occurring January 24th 2022."

Answered by AI

Has Clopidogrel been granted official authorization by the FDA?

"Clopidogrel has been deemed safe enough to reach Phase 4 trials, thus we rate its safety with a 3."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
CES1 Crossover Trial of Clopidogrel and Ticagrelor
Joshua Lewis 2017. "CES1 Crossover Trial of Clopidogrel and Ticagrelor". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03161678.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top